Print 20 comment(s) - last by silentwriter.. on Aug 30 at 5:43 AM

severe jaw deficiency   (Source:
The stem cells, which are tissue repair cells called ixmyelocel-T, are used to re-grow craniofacial tissue

Humans with jawbone deficiencies in need of dental implants could benefit from a new stem cell trial conducted by Michigan researchers. 
Darnell Kaigler, study leader from the University of Michigan School of Dentistry, along with William Giannobile, co-author and director of the Michigan Center for Oral Health Research, and Aastrom Biosciences Inc. collaborated to create a stem cell-based method for bone regeneration. 
"In patients with jawbone deficiencies who also have missing teeth, it is very difficult to replace the missing teeth so that they look and function naturally," said Kaigler. "This technology and approach could potentially be used to restore areas of bone loss so that missing teeth can be replaced with dental implants."
The stem cells, which are tissue repair cells called ixmyelocel-T, are used to re-grow craniofacial tissue. They are taken from bone marrow from the patient's own hip and grown using Aastrom Biosciences Inc.'s proprietary system. 
To put ixmyelocel-T to the test, the team conducted a human trial where 24 patients with jawbone deficiencies and missing teeth were split into two groups: one that received the stem cell treatment, and the other that received convention bone regeneration treatment. 
The stem cells were placed into the mouth and jaw. Patients were observed after six and 12 weeks, and according to the results, those receiving the stem cell treatment experienced faster bone repair and greater bone density than those with traditional bone therapy. Also, the stem cell group required less secondary bone grafting for implants. 
This type of treatment could be used for those born with defects or those who've suffered trauma or certain diseases. However, more clinical trials are required before these stem cell therapies can be used regularly. 

Source: Eurekalert

Comments     Threshold

This article is over a month old, voting and posting comments is disabled

By geddarkstorm on 8/2/2012 1:33:23 PM , Rating: 2
Embryonic stem cells provide nothing that we don't have from adult stem cells, except problems. The vast majority of embryonic cells carry lethal mutations that prevent full embryonic development (that is, most conceptions fail, and we alive today are the lucky few). If a gene is defective in adult stem cells, it's simple to homologous recombine a fixed version in; trying to match an entire foreign genome is a very different thing.

Embryonic stem cells are not "more recently discovered", having been known since the 1960's. Adult stem cells are the recent discovery, as it was believed for ages that nothing but your liver, skin, and marrow could regenerate, but we've been finding more stem cells for different tissues (including the brain and heart) just this past decade. We can also now revert cells back to the pluripotent (embryonic like, minus the accessory cells that make the placenta) stage with incredible ease. Harvesting from embryos is never necessary, needlessly complex, offers complications and no benefits over our other methods.

ACT's trials are on going, and no results have yet been released; it's not complete. Geron halted its trial, for reasons unspecified, and have given up completely on such stem cell treatments (again, for reasons unspecified). See: . Cancer takes years to appear, and none of these trials have been going more than months.

"Young lady, in this house we obey the laws of thermodynamics!" -- Homer Simpson

Copyright 2016 DailyTech LLC. - RSS Feed | Advertise | About Us | Ethics | FAQ | Terms, Conditions & Privacy Information | Kristopher Kubicki